Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher D Payne

Showing results (11-20 of 40) with videos related to

Pageof 4
Sort By:
British Journal of Clinical Pharmacology|February 21, 2006
Tadalafil pharmacokinetics in healthy subjectsS Thomas Forgue, Beverley E Patterson, Alun W Bedding, et al.
Current Medical Research and Opinion|September 13, 2008
Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrelDavid S Small, Nagy A Farid, Ying G Li, et al.
Advances in Therapy|March 21, 2025
Pharmacokinetic Comparability and Safety Between Original and Citrate-Free Mirikizumab Formulations for Subcutaneous Injections: Results from Three Clinical TrialsYuki Otani, Brian G Feagan, Geert R D'Haens, et al.
Clinical Pharmacokinetics|November 9, 2010
Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrelDavid S Small, Nagy A Farid, Christopher D Payne, et al.
Journal of Clinical Pharmacology|December 21, 2007
Prasugrel, a new thienopyridine antiplatelet drug, weakly inhibits cytochrome P450 2B6 in humansNagy A Farid, Christopher D Payne, C Steven Ernest, et al.
European Heart Journal|April 20, 2006
Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery diseaseTomas Jernberg, Christopher D Payne, Kenneth J Winters, et al.
Pharmaceutical Research|May 4, 2021
Subcutaneous Injection Site Pain of Formulation MatricesGalen H Shi, Karthik Pisupati, Jonathan G Parker, et al.
Platelets|August 21, 2014
The effect of prasugrel on ADP-stimulated markers of platelet activation in patients with sickle cell diseaseJoseph A Jakubowski, Chunmei Zhou, Kenneth J Winters, et al.
British Journal of Clinical Pharmacology|July 28, 2006
Effects of gender, age, diabetes mellitus and renal and hepatic impairment on tadalafil pharmacokineticsS Thomas Forgue, Diane L Phillips, Alun W Bedding, et al.
Advances in Therapy|November 28, 2025
One Subcutaneous 2-ml Injection of Mirikizumab is Bioequivalent to Two 1-ml Subcutaneous Injections in Healthy ParticipantsYuki Otani, Christopher D Payne, Edward V Loftus, et al.
Pageof 4

Showing results (11-20 of 40) with videos related to

Sort By:
Pageof 4
British Journal of Clinical Pharmacology|February 21, 2006
Tadalafil pharmacokinetics in healthy subjectsS Thomas Forgue, Beverley E Patterson, Alun W Bedding, et al.
Current Medical Research and Opinion|September 13, 2008
Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrelDavid S Small, Nagy A Farid, Ying G Li, et al.
Advances in Therapy|March 21, 2025
Pharmacokinetic Comparability and Safety Between Original and Citrate-Free Mirikizumab Formulations for Subcutaneous Injections: Results from Three Clinical TrialsYuki Otani, Brian G Feagan, Geert R D'Haens, et al.
Clinical Pharmacokinetics|November 9, 2010
Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrelDavid S Small, Nagy A Farid, Christopher D Payne, et al.
Journal of Clinical Pharmacology|December 21, 2007
Prasugrel, a new thienopyridine antiplatelet drug, weakly inhibits cytochrome P450 2B6 in humansNagy A Farid, Christopher D Payne, C Steven Ernest, et al.
European Heart Journal|April 20, 2006
Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery diseaseTomas Jernberg, Christopher D Payne, Kenneth J Winters, et al.
Pharmaceutical Research|May 4, 2021
Subcutaneous Injection Site Pain of Formulation MatricesGalen H Shi, Karthik Pisupati, Jonathan G Parker, et al.
Platelets|August 21, 2014
The effect of prasugrel on ADP-stimulated markers of platelet activation in patients with sickle cell diseaseJoseph A Jakubowski, Chunmei Zhou, Kenneth J Winters, et al.
British Journal of Clinical Pharmacology|July 28, 2006
Effects of gender, age, diabetes mellitus and renal and hepatic impairment on tadalafil pharmacokineticsS Thomas Forgue, Diane L Phillips, Alun W Bedding, et al.
Advances in Therapy|November 28, 2025
One Subcutaneous 2-ml Injection of Mirikizumab is Bioequivalent to Two 1-ml Subcutaneous Injections in Healthy ParticipantsYuki Otani, Christopher D Payne, Edward V Loftus, et al.
Pageof 4